The Albanese Government has effectively rejected or obfuscated most of the committee's recommendations, but that does not mean the response has no value or cannot contribute to positive change. Stakeholders must understand the nuance and recognise the real opportunities because these processes never deliver the 'magic bullet'.
A minimalist but entirely predictable response - the opportunities are in the nuance
December 1, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
Australia cannot afford complacency on life sciences, AusBiotech warns at 40
October 8, 2026 - - Latest News -
Life sciences sector warns that tax overhaul could push clinical trials offshore
October 8, 2026 - - Latest News -
Moderna and CSIRO launch five year biosecurity collaboration focused on Hendra vaccine
October 8, 2026 - - Latest News
